Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized 
by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute 
renal failure. HUS may be caused by several different conditions, including 
infection, malignancy, and chemotherapeutic agents, such as mitomycin, 
cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced 
HUS is poor, and the disease has a high mortality rate. This study reports a 
case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.